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Interest in extracellular RNA (exRNA) has intensified as evidence accumulates that these
molecules may be useful as indicators of a wide variety of biological conditions. To estab-
lish specific exRNA molecules as clinically relevant biomarkers, reproducible recovery from
biological samples and reliable measurements of the isolated RNA are paramount.Toward
these ends, careful and rigorous comparisons of technical procedures are needed at all
steps from sample handling to RNA isolation to RNA measurement protocols. In the inves-
tigations described in this methods paper, RT-qPCR was used to examine the apparent
recovery of specific endogenous miRNAs and a spiked-in synthetic RNA from blood plasma
samples. RNA was isolated using several widely used RNA isolation kits, with or without
the addition of glycogen as a carrier. Kits examined included total RNA isolation systems
that have been commercially available for several years and commonly adapted for extrac-
tion of biofluid RNA, as well as more recently introduced biofluids-specific RNA methods.
Our conclusions include the following: some RNA isolation methods appear to be supe-
rior to others for the recovery of RNA from biological fluids; addition of a carrier molecule
seems to be beneficial for some but not all isolation methods; and quantitative recovery
of RNA is observed from increasing volumes of cerebrospinal fluid.
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INTRODUCTION
A leading goal of modern biomarker studies is to ascertain disease
conditions and other biological states by examining molecules in
easily obtained biological fluids. For example, the ability to use
blood-based markers for diagnosis, location, and staging of can-
cer, or to predict outcome of several therapeutic options, would
have several benefits, from early detection to obviating the need
for invasive and expensive biopsies. While some biomarkers may
simply be “bystanders” in the disease process, others might be
actively involved and thus present targets for novel therapeutics
(Kota et al., 2009; Cho, 2012; Lindow and Kauppinen, 2012). Of
course, any successful marker or set of markers would need to
be sufficiently stable during and following the isolation process
to allow reliable detection and measurement. Among the many
types of biomolecules currently under investigation as potential
biomarkers are extracellular RNA (exRNA), including microRNA
(miRNA) (Pritchard et al., 2012a). These short oligonucleotides
are thought to be stable in extracellular fluids, protected from
degradation by ubiquitous RNases (Mitchell et al., 2008) within or
even on the surface of small particles.
Many questions about extracellular miRNAs are under active
investigation. The identities of the various particles that carry and
protect miRNAs, the frequency of miRNA association with differ-
ent particle types, and the relative contributions of these particles
to exRNA profiles in health and disease have yet to be firmly
established (Witwer et al., 2013). The extent to which miRNAs
are specifically or non-specifically associated with particle types
is also largely unknown. Finally, the extent and mechanisms of
function of extracellular miRNAs – e.g., in intercellular signal-
ing – remain incompletely understood,although numerous studies
have established that such functions exist (Valadi et al., 2007; Peg-
tel et al., 2010; Ismail et al., 2012). In the face of these many
outstanding questions, the current consensus is that extracellu-
lar vesicles (Lotvall and Valadi, 2007), protein complexes (Arroyo
et al., 2011; Turchinovich et al., 2011), and, possibly, additional
particles (Turchinovich et al., 2012), contribute to the extracel-
lular population of miRNAs. Furthermore, specific extracellular
miRNAs or constellations of miRNAs appear to be co-regulated
during disease: to give just a few of many examples, in cancers
(Cho, 2011), acute retroviral infection (Witwer et al., 2011), and
autoimmune disease (Murata et al., 2010).
The promise of extracellular miRNA biomarkers is tremen-
dous, but several obstacles must be surmounted during ongoing,
successful development of miRNA signatures of disease and other
conditions. First, many high-profile preclinical studies in general
cannot be replicated or reproduced (Ioannidis, 2005; Ioannidis
et al., 2009); in the same way, many miRNA profiling studies
are underpowered or analysis cannot be replicated because data
are missing or procedures inadequately explained (Baggerly, 2013;
Witwer, 2013). In some cases, then, better study design and report-
ing would be helpful. Second, lack of standardization is a challenge
to much-needed comparisons of miRNA studies. Biological flu-
ids contain small amounts of RNA relative to cells and tissues;
if sample processing does not remove small cells and cell frag-
ments, miRNAs from these particles may predominate in any
“extracellular” miRNA profile (McDonald et al., 2011), just as
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RNA from hemolysed samples may affect profiling (Kirschner
et al., 2011; Pritchard et al., 2012b). A study of miRNAs in
platelet-rich plasma – say, plasma that has been spun for 10 min
at 800× g – might simply reflect disease state-associated platelet
abundance. Third, because of the aforementioned relative paucity
of RNA in cell-free fluids as well as the presence of PCR inhibitors
in biological fluids, efficient extraction methods are needed to
ensure maximum recovery of RNA from low volumes of input
fluid.
While several studies have described methods for RNA extrac-
tion from cell-free fluids (Tzimagiorgis et al., 2011; Debey-Pascher
et al., 2012) or total blood (including cells) (Gaarz et al., 2010),
relatively few studies have specifically compared the use of com-
mercially available kits for RNA extraction from biofluids (Burgos
et al., 2013) or constituents of biofluids (Eldh et al., 2012). We are
unaware of any such studies employing recently released biofluids-
specific RNA extraction methods from Qiagen and Exiqon. Here,
we report comparisons of five commercially available kits/methods
for RNA extraction from plasma; the effects of including or omit-
ting glycogen as a carrier/co-precipitant; and the linear recovery of
RNA from increasing volumes of plasma and cerebrospinal fluid
(CSF) using a biofluids-specific method.
MATERIALS AND METHODS
ETHICS STATEMENT
De-identified plasma was from a healthy donor who provided
informed consent in accordance with approval by the Johns Hop-
kins Institutional Review Board. CSF was from a healthy donor
pigtailed macaque (Macaca nemestrina). Animal studies were
approved by the Johns Hopkins University Institutional Animal
Care and Use Committee and conducted in accordance with the
Weatherall Report, the Guide for the Care and Use of Labora-
tory Animals, and the USDA Animal Welfare Act. Macaques are
pair- or group-housed when possible and receive environmental
enrichment including manipulanda, foraging, and opportunity to
exhibit species-specific behavior. Animals are continually moni-
tored for signs of distress. Ketamine is administered for blood or
CSF draws.
REAGENTS
Paired stem-loop reverse transcription primers and hydrolysis
probe/primer combinations for RT-qPCR were purchased from
Life Technologies for the following miRNAs: endogenous mam-
malian miRs-16, -21, -34a, -126, and -150, and exogenous cel-miR-
39. These miRNAs, along with most relatively abundant miRNAs,
are conserved amongst primates (Brameier, 2010; Shao et al.,
2010). RNA isolation kits were from Life Technologies (mirVana,
AM1561), Exiqon (miRCURY RNA Isolation Kit – Cell and Plant,
#300110; and miRCURY RNA Isolation Kit – Biofluids, #300112),
and Qiagen (miRNeasy Serum/Plasma Kit, # 217184). TRIzol LS
reagent was purchased from Life Technologies (#10296-010). Taq-
Man microRNA Reverse Transcription Kit (#4366596) and qPCR
master mix (#4440047) were purchased from Life Technologies.
iScript select cDNA synthesis kit (1708897) and SsoFast qPCR mix
(1725232) were from BioRad. Additional reagents included glyco-
gen (Ambion/Life Technologies, AM9510), synthetic cel-miR-39
(Integrated DNA Technologies – custom product synthesized to
sequence from miRbase.org) (Mitchell et al., 2008), and highly
pure diethyl pyrocarbonate (DEPC)-free and nuclease-free water
(Qiagen, 129115).
RNA HANDLING AND STORAGE
We followed RNase-free protocols throughout all procedures up
to qPCR setup (after RNA has been converted to cDNA). A lam-
inar air flow cabinet dedicated to RNA work was used for RNA
isolation and reverse transcription preparations. Surfaces (cab-
inet, racks, pipettes, centrifuge) were cleaned thoroughly with
RNase-away prior to and after use. Pipettes and other portable
objects to be used in the hood were exposed to UV light in a UV
crosslinker for 2 min on each side. This was done to avoid intro-
duction of contaminating nucleic acids and, potentially, proteins.
We implemented double-gloving, regular glove changes, and wear-
ing of Tyvek sleeves or clean lab coats. Certified RNase-free barrier
pipette tips were used. Where possible, all reagents were certified
RNase-free. Isolated RNA from all isolation methods was stored at
−80˚C.
All RT-qPCR reactions were performed with once-thawed RNA
as substrate. RNA samples were thawed on ice, mixed gently,
and centrifuged at 2500× g for 5 min in a table-top centrifuge
before use. This was done because some column-based clean-up
methods introduced a fine white powder into the eluted sample,
presumably from the filter materials. Although this material is
likely inert, we pelleted it to avoid interference with downstream
reactions. It may be preferable to pellet this material and transfer
the clarified supernatant to a new RNase-free tube prior to initial
freezing.
SAMPLE HANDLING
RNA isolations were performed from platelet-poor primate
plasma that had been frozen (−80˚C) and thawed once. Platelet-
poor plasma was defined as plasma separated from blood cells less
than 30 min following blood draw with a 1000× g spin for 15 min
at room temperature followed by a 2500× g spin for 15 min at
room temperature to remove most remaining platelets. Plasma
was obtained from blood collected into ACD anticoagulant. All
methods comparison experiments were conducted with aliquots
of plasma from a single blood draw from one donor.
RNA ISOLATIONS
For all isolations, 5 or 10 pg synthetic cel-miR-39 per isolation was
spiked into the respective lysis/denaturant buffer before combin-
ing with plasma. We note that synthetic RNA cannot be added
directly to plasma or other biological substances because endoge-
nous RNases degrade it immediately (Mitchell et al., 2008). Also,
fresh cel-miR-39 dilutions were prepared for each set of isola-
tion experiments since storing highly diluted RNA could result
in substantial loss of material to container surfaces. Three micro-
grams highly pure glycogen (as indicated) per isolation was either
omitted (negative) or added (positive) as a carrier/co-precipitant.
We emphasize the importance of mixing samples well (includ-
ing, where appropriate, vigorous vortexing for at least 1 min
prior to centrifugation for phase separation). Screw-cap tubes
are recommended to minimize losses during organic extraction
methods.
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Comparison of three RNA isolation methods, with and without
glycogen
To compare mirVana, miRCURY Cell and Plant, and TRIzol LS
isolation with mirVana column clean-up, triplicate isolations for
each method were performed from 100µl plasma each, both with
and without glycogen (see above) for a total of 18 isolations. Manu-
facturer’s protocols were followed for the Exiqon and Ambion/Life
Technologies kits. For TRIzol LS/column clean-up, 100µl plasma
was diluted with 150µl nuclease-free water, followed by addition
of 750µl TRIzol LS reagent. Samples were mixed and incubated at
room temperature for 10 min. Two-hundred microliters chloro-
form was added with a glass pipette, followed by vortexing for
1 min and incubation at room temperature for 5 min. Phases
were separated by centrifugation at 14,000× g for 15 min in an
Eppendorf 4514C centrifuge. Aqueous layer was removed, and 1.5
volumes EtOH were added. This mixture was applied to mirVana
kit filter columns followed by wash and elution steps as per man-
ufacturer’s protocol. For this isolation experiment, the miRNAs
measured were endogenous miR-16 and miR-21 and spiked-in cel-
miR-39. miRNAs were measured by RT-qPCR in triplicate for each
isolation.“Fold abundance”was calculated in comparison with the
average of results for the three no-glycogen mirVana isolations.
Comparison of Exiqon miRCURY cell and plant kit and Exiqon
miRCURY biofluids kit
Duplicate isolations from 100µl plasma were done for each
method. Glycogen was added for isolations using both methods;
a no-glycogen condition was included only for the Biofluids Kit,
for a total of six isolations. The manufacturer’s protocols were
followed. miRNAs measured included endogenous miRs-16, -34a,
and -126, and spiked-in cel-miR-39. miRNAs were measured by
RT-qPCR in triplicate for each isolation. “Fold abundance” was
calculated in comparison with the average of results for the two
glycogen-added miRCURY Cell and Plant isolations.
Exiqon biofluids versus Qiagen plasma/serum kits
Triplicate isolations were done for each method from 200µl
plasma. Glycogen was added for all isolations. Manufacturers’
protocols were followed. Triplicate RT-qPCR reactions were per-
formed with material from each isolation to measure endogenous
miRs-16 and -150 and exogenous spike-in cel-miR-39. Fold abun-
dance for the Qiagen isolations was calculated against the mean
of results for the three Exiqon Biofluids isolations. Separately, for
the Qiagen kit, different elution volumes (50 and 100µl) were
compared with the manufacturer-recommended 14µl.
Cerebrospinal fluid RNA isolation
RNA was isolated by the Exiqon Biofluids method with addition of
glycogen and spike-in to all isolations. About 50, 100, and 200µl
CSF were used as input volume. Duplicate isolations were per-
formed for each input volume. Higher-abundance miRs-16 and
-223 and lower-abundance miR-21 and let-7c were measured in
triplicate reactions.
REVERSE TRANSCRIPTION AND REAL-TIME QUANTITATIVE PCR
Reverse transcription and RT-qPCR steps were performed largely
according to the manufacturer’s protocols, with any modifications
as described previously.(Witwer et al., 2011, 2012) The stem-
loop RT primer design allows specific amplification of mature
miRNA; no significant differences are seen in DNase-treated versus
untreated samples. Following reverse transcription, samples were
diluted with 20 or 30µl RNase-free water and were mixed, spun
down, and stored at−20˚C until use. The Applied Biosystems/Life
Technologies recommended protocol for qPCR reaction setup was
modified for a smaller volume of 10µl per well before addition
of sample, using the same reagent proportions as recommended
by the manufacturer. To each well, 2µl of diluted cDNA was
added. Each plate was mixed gently, centrifuged, and loaded into
the real-time machine. The manufacturer’s amplification protocol
was followed for 45 amplification cycles. Negative controls: no-
template and/or no-reverse transcriptase control reactions were
performed for selected isolations, substituting water for RNA
or the reverse transcriptase enzyme. These reactions consistently
failed to amplify or amplified only after 40 PCR cycles on average
(data not shown). Reverse transcription and RT-qPCR reagents
were from Life Technologies for all experiments except for the
Exiqon Biofluids/Qiagen miRNeasy comparison, for which Bio-
Rad reagents were used (we conducted a side-by-side comparison
of the reagents and found no significant differences in results).
Real-time detection systems were the iQ5 and CFX96 instruments
(both from BioRad, Hercules, CA, USA).
DATA COLLECTION AND PROCESSING
To obtain Cq values, appropriate thresholds were drawn man-
ually (iQ5) or automatically (CFX96) with checking and manual
adjustment by the operator if needed. Mean Cq and standard devi-
ation were calculated for each technical triplicate reaction for each
miRNA. Mean Cq and standard deviation (for three isolations)
or range (for two isolations) were determined for each type of
isolation. Delta Cq values were calculated with reference to the
chosen “control” condition for each isolation experiment, as spec-
ified above. From these values, fold abundance with respect to the
control was calculated (Livak and Schmittgen, 2001). Mean fold
abundance values and standard deviations were determined for
the examined miRNAs.
RESULTS
Five RNA isolation methods/kits were compared for isolation of
small RNA from human plasma. All but one method was tested
in the presence and absence of glycogen as RNA carrier. Because
assessment of different RNA isolation methods requires the use
of a standard source sample, we conducted all isolations from
plasma obtained from a single blood draw from a single donor.
This plasma had been centrifuged twice to obtain platelet-poor
plasma as described in methods. Aliquots of plasma had been
frozen at−80˚C and had not been thawed previously.
The low abundance of exRNA necessitates consideration of a
carrier molecule. We chose glycogen as a carrier rather than com-
plex exogenous RNA mixtures such as yeast tRNA or MS2 phage
RNA. Little has been published on this topic, but there seem to be
conflicting opinions on whether biological carrier RNAs might
be responsible for non-specific hybridization or amplification
in downstream analytics. Highly pure glycogen is an alternative
carrier/co-precipitant that may avoid these unresolved questions
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since it is inert and does not cause reported interference with
downstream assays (Turchinovich et al., 2011; Turchinovich and
Burwinkel, 2012). Still, since glycogen is purified from biological
sources, chiefly bivalves, some commercial glycogen preparations
may contain nucleic acids. As a result, UV-treated glycogen or an
alternative co-precipitant, linear polyacrylamide (LPA), have been
proposed (Bartram et al., 2009). In tests of the glycogen we used,
however, we were unable to obtain specific signal for any of the
mammalian miRNAs or other small RNAs examined (data not
shown).
In addition to glycogen, we used a synthetic spiked-in cel-miR-
39 RNA. It is important to remember that the spike-in is useful for
assessment of recovery but cannot be used for biological normal-
ization. In the experiments described here, no normalization was
necessary, since the same plasma sample was used throughout.
As noted in Section “Materials and Methods,” fresh dilutions of
cel-miR-39 stock were made for each of three successive isolation
experiments; thus,normalization by spike-in between experiments
would be inappropriate and was not done.
We first compared the Ambion mirVana kit [based on (Chom-
czynski and Sacchi, 1987)] with the Exiqon miRCURY Cell and
Plant Kit and TRIzol LS extraction followed by mirVana column
clean-up. Each of these three protocols was performed in tripli-
cate with and without the use of glycogen as a carrier. The mirVana
and TRIzol LS methods include a phase separation step, whereas
the miRCURY method does not. Thus, the miRCURY protocol
is faster, less technically demanding, and is likely subject to less
technical variation, operator-dependent, and otherwise.
To assess performance of these kits, two endogenous miRNAs
and the spike-in were measured in triplicate for each isolation
replicate by RT-qPCR. (Please observe that we use the term“recov-
ery” or “apparent recovery” to describe results, although from the
RT-qPCR results it is not necessarily clear whether differences
arise from different RNA recovery efficiencies, different inhibitor
removal efficiencies, or both).
The Ambion mirVana kit yielded similar results with and with-
out glycogen (Figure 1). Without glycogen, the Exiqon protocol
showed slightly lower recovery than both mirVana kit protocols.
Addition of glycogen to the Exiqon protocol significantly enhanced
recovery by more than threefold compared with the no-glycogen
Exiqon method (p< 0.02) or by 1.6-fold versus mirVana (trend,
with p< 0.1). TRIzol isolation followed by column clean-up did
not perform as well as the other methods in our hands (Figure 1).
Surprisingly, the addition of glycogen appeared to exacerbate the
low RNA recovery achieved by this method.
A new, biofluids-specific Exiqon kit became available in Decem-
ber, 2012. According to the manufacturer, this kit allowed better
RNA recovery as well as PCR inhibitor removal in comparison
with other methods. (It should be mentioned that RNA species
less than 1000 nt in length are preferentially recovered.) The two
protocols are similar in terms of time and operator skill require-
ments. We performed a second isolation experiment to compare
the performance of this Biofluids kit (with and without glyco-
gen) with the standard miRCURY kit (with glycogen). For this
experiment, duplicate isolations were performed, followed by trip-
licate miRNA RT-qPCR reactions for each isolation replicate. Both
FIGURE 1 | Comparison of three RNA isolation methods, with and
without glycogen. miRNAs from plasma RNA isolated in triplicate by
the three indicated methods (E, Exiqon Cell and Plant kit; TLS, TRIzol
LS; M, mirVana isolation kit), with and without glycogen, were
assessed by RT-qPCR in triplicate. Results based on two endogenous
and one spiked-in exogenous miRNA are shown. Raw Cq averages and
standard deviations are presented for the higher-abundance miR-16,
lower-abundance miR-21, and spiked-in cel-miR-39. The “combined”
panel shows mean apparent combined abundance of miRNAs in
samples isolated by the mirVana no-glycogen method set equal to one.
Fold abundance (from deltaCq method) is displayed with standard
deviation bars.
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without and with glycogen, the Biofluids kit displayed signifi-
cantly greater recovery than standard miRCURY with glycogen
(Figure 2, p< 0.02 and p< 0.01, respectively), with large fold
abundance differences averaging about six (without glycogen)
or >10 (with glycogen). For qPCR Cq results by all methods,
standard deviation of the technical triplicates was typically below
0.1 for high-abundance miRNAs. For the low-abundance miRNA
miR-34a, high variability was observed.
In a third experiment, conducted with addition of glyco-
gen for all isolations, the miRCURY Biofluids kit was compared
with another biofluids-specific protocol: the Qiagen miRNeasy
Serum/Plasma system. The Qiagen protocol includes a phase sep-
aration and is thus comparable to mirVana and TRIzol protocols
in time and technique requirements. In contrast with the other
methods we tested, the Qiagen protocol calls for a very small elu-
tion volume (14µl), with the apparent intent of providing a more
concentrated RNA sample.
Triplicate isolations were performed followed by triplicate RT-
qPCR measurements of endogenous miRNAs and spiked-in cel-
miR-39. As with all other experiments performed for this report,
we measured miRNAs in 2µl of purified RNA eluted as per
the manufacturers’ protocols. Both kits produced highly consis-
tent results between isolation replicates. Results indicated similar
apparent recovery by the two kits (Figure 3), albeit with slightly
lower recover for the Qiagen kit. However, it must be considered
that the results were obtained with 2µl of elution volumes of 50µl
(Exiqon) versus 14µl (Qiagen). Assuming that RNA was appro-
priately recovered with a 14-µl elution volume, i.e., that RNA was
not left on the column, this might imply lower recovery by the
Qiagen kit. Since we and others have previously observed with
other isolation kits that smaller elution volume does not neces-
sarily produce more concentrated RNA (Witwer et al., 2013), we
performed an additional experiment to determine whether larger
elution volume would recover additional RNA from the Qiagen
columns. In this experiment, duplicate isolations were performed
for 14, 50, and 100µl elution volumes. Most of the RNA was
in fact recovered by the 14-µl volume: practically all of a low-
abundance RNA and ∼70–90% of high- to medium-abundance
RNAs (data not shown). Thus, the apparent difference in recovery
of the Exiqon Biofluids and Qiagen Plasma/Serum kits does not
seem to be addressed by altering the elution volume for the latter.
To investigate quantitative recovery of RNA using the Exiqon
Biofluids kit, we isolated RNA from 50, 100, and 200µl of plasma
and from the same volumes of Macaca nemestrina CSF from a
single donor. The same amount of spike-in RNA was added to
each isolation. In the case of plasma, endogenous miRNA had
greater apparent recovery with increasing input volume, but the
increase was not proportional from 100 to 200µl input (Figure 4).
Although we examined only three endogenous miRNAs, the lower-
abundance miR-126 in particular displayed no apparent increase
in recovery at 200µl (Figure 4). Interestingly, cel-miR-39 was
measured at a lower level in the 200-µl input samples, suggesting
inefficient apparent recovery because of column clogging and/or
concentration of inhibitors. In contrast, largely quantitative recov-
ery was observed from increasing volumes of input CSF (Figure 5),
a fluid that in health is relatively protein-poor compared with
plasma. Spiked-in cel-miR-39 was recovered at the same level with
each volume of input.
FIGURE 2 | Comparison of Exiqon miRCURY Cell and Plant and
miRCURY Biofluids kits. Results of plasma miRNA RT-qPCR (technical
triplicates) of duplicate isolations by the two Exiqon methods, with
miRCURY Cell and Plant conducted with glycogen and Biofluids conducted
both with and without glycogen. Fold abundance is relative to Exiqon
miRCURY Cell and Plant. Bars represent range. Results of RT-qPCR for
three endogenous and one spiked-in miRNA are shown. As noted in the
text, the depicted differences versus Exiqon miRCURY Cell and Plant were
significant.
FIGURE 3 | Comparison of two biofluids-specific kits. Triplicate plasma
RNA isolations with Exiqon Biofluids and Qiagen miRNeasy Serum/Plasma
(glycogen added for both) were compared in triplicate RT-qPCR reactions for
two endogenous and one spiked-in miRNA. Fold abundance is relative to
Exiqon Biofluids. Note that for the Exiqon and Qiagen kits, the eluate
volumes were 50 and 14µl, respectively, as specified by the manufacturers’
protocols, so the results are not necessarily directly comparable (see text).
DISCUSSION
Our results indicate that the Exiqon miRCURY Biofluids Kit out-
performs other RNA isolation methods we tested, at least for isola-
tion of small RNAs from plasma. This finding, furthermore, should
be viewed in light of the relative ease of execution of the Exiqon
method when compared with traditional phase-separation-based
methods. Ease of use and short processing time are certainly
appropriate considerations when results are not compromised.
Without glycogen, the standard Exiqon miRCURY slightly
underperformed, and with glycogen, it slightly outperformed the
Ambion mirVana kit. Both kits outperformed TRIzol LS with col-
umn clean-up in our hands. The new Exiqon miRCURY Biofluids
kit appeared to be superior for small RNA isolation when com-
pared with the standard miRCURY kit. With miRCURY Biofluids,
all miRNAs were apparently recovered at higher quantities in the
presence of glycogen, although the difference was not statistically
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FIGURE 4 | Quantitative recovery of RNA from plasma does not extend
to highest input volume. The Exiqon Biofluids kit was used to isolate RNA in
duplicate isolations for each of the three indicated quantities of plasma.
Range of Cq values for higher-abundance miR-16, lower-abundance miRs-21
and -126, and spiked-in cel-miR-39 (same input amount for each isolation) are
shown.
FIGURE 5 | Quantitative recovery of RNA from cerebrospinal fluid by
Exiqon Biofluids. The Exiqon Biofluids kit was used to isolate RNA in
duplicate isolations for each of three quantities of CSF. Linear response to
input volume is shown for four endogenous miRNAs as indicated
(measured in triplicate for each isolation), as well as spiked-in cel-miR-39
(same input amount for each isolation). Bars represent range of Cq values
for the duplicate isolations.
significant at an alpha of 0.05. miRCURY Biofluids also pro-
vided better recovery than the Qiagen miRNeasy Serum/Plasma
kit in our hands, considering the small elution volume from the
Qiagen kit.
Although we found that the Qiagen Serum/Plasma kit allowed
recovery of most of the on-column RNA with only 14µl of
eluant, it is not clear to us that using smaller elution volumes
generally achieves greater RNA concentration. For some protocols
and columns, smaller volumes of eluant may simply leave RNA
on the column rather than providing greater concentration. An
analogy that has been used previously (Eldh et al., 2012, Inter-
national Society for Extracellular Vesicles Workshop in New York
City) likened the column filter to a rag: to rinse it, the rag must
be soaked completely (Witwer et al., 2013). Thus, we would rec-
ommend that any attempts to concentrate RNA in this manner
be tested rigorously. Overall, additional optimization of existing
methods is encouraged, since repeated extractions and tempera-
ture during isolation (Burgos et al., 2013), different carriers and
spike-ins, and elution volumes are among the parameters that
could be optimized for specific RNA isolation kits.
A conclusion from our experiments that we found particularly
surprising is that TRIzol LS isolation followed by column clean-up
did not perform well in our hands. We are uncertain as to why this
method performed so poorly in our case or why the addition of
glycogen appeared further to decrease yield, since this method or
variations on it have been used with excellent results by others. The
variability and low yield we report here is likely due to a separate
issue from that reported by Kim et al. (2012b), who retracted their
Cell article in 2012 after observing that standard TRIzol extraction
resulted in apparently poor recovery of low-GC-content miRNAs
from low-abundance samples. However, clarity on this point has
yet to be achieved.
We submit that our results prompt at least three additional
recommendations. First, based on our input volume experiments,
it would appear that using 200µl of plasma as input does not
necessarily result in quantitatively greater recovery. This echoes
previous findings (Kim et al., 2012a). In contrast, RNA was quan-
titatively recovered from the smallest to the largest input volume
of CSF. Thus, it may be important to determine optimal input
volume for each biofluid and isolation method. Second, we would
like to emphasize the importance of co-isolation of all RNA sam-
ples that are that are to be compared within an experiment to
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avoid introduction of batch effects (as we have noted previously)
(Witwer et al., 2011, 2012; Sisk et al., 2012). Although raw Cq values
for spike-in and endogenous miRNA measurements were highly
consistent within each isolation experiment, they varied somewhat
from experiment to experiment. For the spike-in, this may be due
at least in part to the fact that we made a new dilution of spike-in
for each isolation experiment from a highly concentrated stock.
However, it is also clear that batch isolations (and batch RT reac-
tions) should not be compared directly. Third, the Cq differences
between replicate isolations, while often half a cycle or less, indicate
that technical differences could contribute to apparent differences
in miRNA expression, especially in studies with low “n.” Many
miRNA publications report differential expression of twofold or
less. This underlines the importance of proper numbers of biolog-
ical replicates and may also indicate that, where possible, multiple
isolations from the same sample could increase rigor.
This study has several limitations, which may be helpful to
review as they indicate opportunities for advances in the field. We
measured a limited number of endogenous miRNAs in this study.
It is possible that recovery may differ from one method to another
on a miRNA-by-miRNA basis, similar to the differences reported
by Kim et al. (2012b), in their retraction letter. This could be due
to GC content, length, or other features. Assuming availability of
appropriate resources, a miRNome-wide comparison of isolation
methods might be highly useful. Also, we have not determined
whether the differences we observe are due to inhibitors, to dif-
ferential RNA recovery, or to some ratio of the two. Additional
studies would be needed to make this determination. Many RNA
isolation kits are available, along with many method modifications,
and we have explored only a small portion of this methods space.
We encourage other researchers to join us in comparing methods
and working toward standardization as well as improvement of
existing practices. Finally, we have examined only whole platelet-
poor plasma in our methods comparisons. Other biofluids are also
important potential sources of biomarkers, and comparatively lit-
tle methodologic information is available for most biofluids [see,
however (Burgos et al., 2013), published during review of this
paper]. It is also possible that different isolation methods are bet-
ter suited to recovering RNA from specific sub-populations of the
various carrier particles that protect RNA in plasma and other
biofluids. For example, isolation methods for exosomal RNA have
been rigorously compared (Eldh et al., 2012). Similar studies for
other RNA carriers would be informative and would help to estab-
lish whether different methods are needed, e.g., for isolation from
whole plasma versus extracellular vesicles or protein complexes.
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